Brokerages Set Roivant Sciences Ltd. (NASDAQ:ROIV) Price Target at $25.19

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given an average rating of “Moderate Buy” by the ten ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $25.1875.

A number of analysts have commented on the company. HC Wainwright boosted their target price on Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Wall Street Zen upgraded shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings raised shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. Jefferies Financial Group lifted their target price on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Finally, Citigroup upped their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th.

Insider Transactions at Roivant Sciences

In related news, CEO Eric Venker sold 75,000 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $22.53, for a total transaction of $1,689,750.00. Following the sale, the chief executive officer owned 1,654,597 shares of the company’s stock, valued at $37,278,070.41. This trade represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mayukh Sukhatme sold 1,018,995 shares of Roivant Sciences stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total value of $22,122,381.45. Following the sale, the insider owned 20,267,429 shares of the company’s stock, valued at approximately $440,005,883.59. This represents a 4.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 13,004,502 shares of company stock worth $276,813,961 in the last quarter. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of ROIV. Rubric Capital Management LP lifted its position in Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after buying an additional 2,603,260 shares during the period. State Street Corp grew its holdings in Roivant Sciences by 4.8% in the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after buying an additional 911,827 shares during the period. Two Seas Capital LP increased its stake in shares of Roivant Sciences by 4.6% during the 2nd quarter. Two Seas Capital LP now owns 10,598,040 shares of the company’s stock valued at $119,440,000 after acquiring an additional 461,733 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Roivant Sciences by 18.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company’s stock worth $140,839,000 after acquiring an additional 1,423,074 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Roivant Sciences by 12.7% in the second quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company’s stock worth $50,787,000 after acquiring an additional 506,219 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Trading Up 1.7%

ROIV stock opened at $21.98 on Monday. The firm has a 50 day moving average of $21.12 and a 200-day moving average of $16.07. The company has a market cap of $15.29 billion, a price-to-earnings ratio of -39.25 and a beta of 1.22. Roivant Sciences has a 12-month low of $8.73 and a 12-month high of $23.47.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.